rich 1.0 This week's BioPharm Brief highlights City Therapeutics' efforts to advance its RNAi pipeline with a new financing round, positive Phase 3 data for survodutide in obesity and MASLD, and Lilly's oral GLP-1 Foundayo outperforming oral semaglutide in a landmark head-to-head type 2 diabetes trial. The BioPharm Brief https://audioboom.com/channels/5167274-the-biopharm-brief Audioboom https://audioboom.com 480 95 https://audioboom.com/i/43690159/600x600/c 600 600 <iframe width="100%" height="95" src="https://embeds.audioboom.com/posts/8914645/embed?v=202301" style="background-color: transparent; display: block; padding: 0; width: 100%" frameborder="0" allowtransparency="allowtransparency" scrolling="no" title="Audioboom player" allow="autoplay" sandbox="allow-downloads allow-forms allow-popups allow-same-origin allow-scripts allow-storage-access-by-user-activation allow-top-navigation-by-user-activation"></iframe>